Awaiting product image

Article: P.36 Phase 2, open-label, multicenter study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (FIGHT-203)

€2.42

SKU: product-article-15551 Category:

Description

P.36 Phase 2, open-label, multicenter study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (FIGHT-203)

Reviews

There are no reviews yet.

Be the first to review “Article: P.36 Phase 2, open-label, multicenter study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (FIGHT-203)”

Your email address will not be published. Required fields are marked *

Related products